DR. CLAUDE PAUL GENAIN, MD
Medical Practice at Marin Ave, Mill Valley, CA
License number
California A55984
Category
Medical Practice
Type
Specialist
Address
Address
568 Marin Ave, Mill Valley, CA 94941
Phone
(415) 272-9960
(888) 263-1572 (Fax)
(888) 263-1572 (Fax)
Professional information
Dr. Claude P Genain, Mill Valley CA - MD (Doctor of Medicine)
Specialties:
Neurology
Address:
568 Marin Ave, Mill Valley 94941
(415) 272-9960 (Phone), (888) 263-1572 (Fax)
(415) 272-9960 (Phone), (888) 263-1572 (Fax)
Languages:
English, French
Hospitals:
568 Marin Ave, Mill Valley 94941
UCSF Medical Center
505 Parnassus Ave, San Francisco 94143
UCSF Medical Center
505 Parnassus Ave, San Francisco 94143
Education:
Residency Hospital
University Of Ky Hospital Chandler Mc
University Of Ky Hospital Chandler Mc
Animal Model Systems For Viral Pathogenesis Of Neurodegeneration, Autoimmune Demyelination, And Diabetes
US Patent:
2006013, Jun 15, 2006
Filed:
Oct 12, 2005
Appl. No.:
11/248499
Inventors:
Claude Genain - Mill Valley CA, US
Assignee:
CARANTECH, INC. - Mill Valley CA
International Classification:
A01K 67/027
US Classification:
800009000, 800014000
Abstract:
Provided are non-human animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and autoimmune diseases such as diseases of the central nervous system, including multiple sclerosis (MS), and diabetes. Such non-human animal model systems may be suitably employed for the study of diseases such as MS and diabetes and for the identification and characterization of candidate therapeutic compounds and compositions for the treatment of such diseases. Also provided herein are markers and methods for the detection, in patients susceptible to autoimmune disease, of autoimmune diseases of the central nervous system such as progressive multifocal leukoencephalopathy (PML) following treatment with one or more therapeutic agent as exemplified herein by the therapeutic agent natalizumab. Exemplary animal model systems comprise marmosets infected with a herpesvirus such as HHV6-A and HHV6-B, transgenic mouse and zebrafish animal model systems wherein the transgene encodes CD46, and methods for monitoring the risks of patients having MS, diabetes and other auto-immune disorders treated with anti-adhesion molecules such as natalizumab.
Recombinant Antibody Fragments As Autoantibody Antagonists
US Patent:
6569431, May 27, 2003
Filed:
Jul 5, 2001
Appl. No.:
09/899896
Inventors:
Claude P. Genain - Mill Valley CA
Stephen L. Hauser - Ross CA
Stephen L. Hauser - Ross CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39395
US Classification:
4241421, 4241301, 4241331, 4241371, 4241411, 4241431, 4241521, 4241721, 5303871, 5303873, 5303875, 5303881, 53038815, 5303882, 53038822
Abstract:
The invention provides methods and compositions for inhibiting autoantibody binding in demyelinating disease such as multiple sclerosis. The compositions comprise immunoglobulin CDR3 sequences derived from combinatorial phage display libraries selected for high-affinity binding to myelin oligodendrocyte glycoprotein.
Inhibiting Mog-Antibody Binding
US Patent:
6573236, Jun 3, 2003
Filed:
Dec 21, 2001
Appl. No.:
10/026045
Inventors:
Claude P. Genain - Mill Valley CA
Stephen L. Hauser - Ross CA
Stephen L. Hauser - Ross CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 3804
US Classification:
514 2, 514 15, 514 16, 514 17, 514903, 536300, 536328, 536329, 4241841
Abstract:
The invention provides methods and compositions for inhibiting pathogenic binding of an pathogenic autoantibody to a myelin oligodendrocyte glycoprotein (MOG) autoantigen and screening for inhibitors of pathogenic binding of an autoantibody to a MOG autoantigen.
Ngf For The Prevention Of Demyelination In The Nervous System
US Patent:
7282482, Oct 16, 2007
Filed:
May 10, 2001
Appl. No.:
09/854142
Inventors:
Ilse Bartke - Mannheim, DE
Jurgen Unger - Landshut, DE
Claude Genain - Mill Valley CA, US
Stephen Hauser - Ross CA, US
Jurgen Unger - Landshut, DE
Claude Genain - Mill Valley CA, US
Stephen Hauser - Ross CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 38/18
US Classification:
514 12, 514 2
Abstract:
This invention pertains to the discovery that nerve growth factor (NGF) is capable of preventing further demyelination of nervous tissue in pathologies characterized by the demyelination of nervous tissue (e. g. multiple sclerosis). In one embodiment, this invention provides a method for inhibiting demyelination in a subject having an inflammatory disease of a nervous tissue. The method involves administering an effective amount of NGF, an NGF analogue, or an active fragment of NGF where the effective amount is sufficient to downregulate the production of interferon λ by T cells infiltrating the central nervous system and/or to upregulate IL-10 production by glial cells.
Method For Diagnosis And Prognosis Of Multiple Sclerosis
US Patent:
2005000, Jan 13, 2005
Filed:
Oct 10, 2003
Appl. No.:
10/683451
Inventors:
Claude Genain - Mill Valley CA, US
Hans-Christian Von Budingen - Schlier, DE
Til Menge - San Francisco CA, US
Hans-Christian Von Budingen - Schlier, DE
Til Menge - San Francisco CA, US
International Classification:
G01N033/53
US Classification:
435007100
Abstract:
This invention provides methods utilizing detection/quantification of autoantibodies to specific epitopes of myelin components (e.g. to conformational epitope of myelin/oligodendrocyte glycoprotein (MOG)) for the definitive diagnosis, and/or staging or typing, and/or prognosis of multiple sclerosis.
Autoantibody Inhibitors
US Patent:
6333033, Dec 25, 2001
Filed:
Aug 26, 1999
Appl. No.:
9/384036
Inventors:
Claude P. Genain - Mill Valley CA
Stephen L. Hauser - Ross CA
Stephen L. Hauser - Ross CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39395
US Classification:
4241371
Abstract:
The invention provides methods and compositions for inhibiting pathogenic binding of an pathogenic autoantibody to a myelin oligodendrocyte glycoprotein (MOG) autoantigen and screening for inhibitors of pathogenic binding of an autoantibody to a MOG autoantigen.